Stop Costly Trial Amendments Before They Happen: Insights from the Kitsa x Hemex Protocol Development Webinar

Franziska Stemmler, CEO of Hemex AG, made an observation during the Kitsa x Hemex protocol development webinar that stopped the conversation: nearly all protocols she has worked on required amendments. Not most. Nearly all of them.

That observation from a senior CRO executive with direct operational exposure across multinational trials captures a problem the industry already knows statistically but struggles to address structurally. Protocol amendments are not edge cases. For most sponsors and CROs, they are a built-in cost of doing business under current development practices.

The webinar brought together clinical operations, AI infrastructure, and regulatory documentation perspectives to examine why amendments keep accumulating, where the risks originate, and how AI-assisted protocol analysis changes what teams can detect before a study begins. This article is a recap of those discussions. The session was held internally; no public recording or transcript is available. Operational observations attributed to Hemex reflect statements from that session; statistics throughout the article are drawn from independently verifiable external sources, cited in the references below.

The Amendment Problem Has Grown More Expensive

The numbers have moved in the wrong direction. A 2024 Tufts Center for the Study of Drug Development (CSDD) follow-up study of 950 protocols and 2,188 amendments found that the prevalence of protocols with at least one amendment across Phase I through IV trials has increased substantially, rising from 57% in 2015 to 76% by the 2022 data collection period ^[1]. The mean number of amendments per protocol grew 60% to 3.3, up from 2.1 ^[1].

Cost compounds quickly at that frequency. The companion 2016 Tufts CSDD study of 836 protocols established the benchmark direct costs: the median cost to implement a substantial amendment was $141,000 for a Phase II protocol and $535,000 for a Phase III protocol ^[2]. Those figures cover protocol rewrites, regulatory and ethics board resubmissions, patient reconsent, site retraining, and operational disruptions. In multi-country trials, where each national ethics committee or oversight authority typically requires its own review of substantial amendments, the totals climb further.

Beyond direct amendment costs, the timeline consequences are severe. Tufts CSDD's 2024 data show the average time from identifying the need for an amendment to receiving final ethics committee approval is 260 days, with a median of 190 days ^[1]. During that window, investigative sites operate under different protocol versions for an average of 215 days ^[1]. Trials with at least one substantial amendment experienced nearly three times longer durations from first patient in to last patient out compared with trials that required no amendments ^[1]. A separate 2024 Tufts CSDD analysis revised the longstanding per-day-of-delay cost estimates for drug development. The study found that a single day of delay is worth approximately $800,000 in unrealized or lost prescription drug and biologic sales, and approximately $40,000 in direct daily clinical trial costs ^[3]. Both figures are substantially lower than the 1990s-era estimates that have been widely cited for decades, reflecting the shift toward narrower patient populations and specialist therapeutics.

Avoidable vs. Unavoidable: How the Composition Has Shifted

Not all amendments are preventable, and distinguishing preventable ones from structural ones is central to where AI analysis adds genuine value.

The 2016 Tufts CSDD benchmark study found that nearly half of all substantial amendments, specifically 45%, were classified as avoidable, with protocol design flaws, eligibility criteria errors, narrative inconsistencies, and operationally infeasible assessment schedules identified as the primary causes ^[2]. The 2024 follow-up study tells a more nuanced story. Among the 2,188 amendments analyzed, 77% were deemed unavoidable, with regulatory agency requests and changes to study strategy cited as the top reasons ^[1]. That reversal is significant.

What it signals is not that protocol quality has improved. It signals that the composition of amendments has changed. Sponsors have reduced some of the most easily detectable design errors. What remains, proportionally, is driven more by external regulatory requirements and evolving therapeutic contexts. Those are harder to prevent through any upstream intervention.

However, 23% of amendments are still avoidable as of the 2024 data. On a Phase III program incurring a median $535,000 per amendment, that fraction represents a concrete financial target ^[1,2]. And regardless of avoidability, every amendment still triggers the same 260-day implementation clock, the same 215-day period of version fragmentation across sites, and the same compression of downstream timelines. Making the initial protocol as accurate, operationally grounded, and regulatory-aligned as possible matters, even when the amendment that eventually occurs turns out to be driven by an agency request.

ICH E8(R1), finalized in October 2021, directly addresses this problem through its Quality by Design framework ^[4]. The guidance recommends that sponsors identify Critical to Quality (CtQ) factors, the protocol design elements whose integrity, if compromised by errors or poor planning, would undermine the reliability or ethics of the entire study, before the protocol is finalized ^[4]. Section 3.1 frames quality as a design-time discipline rather than a monitoring activity applied after problems surface. ICH E6(R3), adopted at ICH Step 4 on January 6, 2025, incorporated these risk-based quality management principles into Good Clinical Practice requirements for trial conduct ^[5]. Regional adoption timelines and implementation requirements vary; sponsors should confirm the applicable status in each operating jurisdiction.

What the industry has historically lacked is not regulatory direction. It has lacked tools capable of executing that directive at the speed and analytical depth that modern protocol complexity demands.

What Hemex's Operating Experience Confirmed

Hemex AG, a European CRO headquartered in the Basel region of Switzerland, specializes in multinational clinical trial execution for pharmaceutical, biotech, and medtech companies ^[6]. The organization's teams regularly encounter protocols where assumptions made during development do not survive contact with site realities or regulatory scrutiny.

During the webinar, the Hemex perspective on this was direct. Franziska Stemmler described how fragmented workflows between clinical operations, regulatory affairs, and biostatistics allow inconsistencies to accumulate silently across a draft. When protocol sections are built by different functional groups in disconnected document environments, the endpoints stated in the scientific rationale can diverge from the statistical methods section. Eligibility criteria can narrow the feasible patient population without anyone calculating the recruitment impact. Assessment schedules can exceed site capacity without anyone modeling the operational burden.

These gaps do not arise from clinical incompetence. They reflect what happens when development timelines are compressed and cross-functional review depends on sequential document circulation. A Phase II or III protocol developed through conventional workflows can take nine months or longer. Assumptions embedded in early drafts become outdated before final approval, and reviewers working through the document in sequence rarely have the full context of every section simultaneously.

The webinar framed this not as a process discipline problem but as an information architecture problem. The question is whether teams have the analytical infrastructure to surface inconsistencies and risks across all sections of a protocol simultaneously, before they are locked into the document.

How AI Analysis Changes Protocol Risk Detection

Artificial intelligence does not draft a protocol on its own. It analyzes one. That distinction matters for understanding where AI adds genuine value and where generic tools create new problems if applied without appropriate oversight.

A 2025 scoping review published in npj Digital Medicine analyzed 142 peer-reviewed studies on AI applications in clinical trial risk assessment, published between 2013 and 2024 ^[7]. The review found that AI techniques, including machine learning, deep learning with graph neural networks and transformers, and causal machine learning, are being applied across three categories of trial risk: safety, efficacy, and operational ^[7]. For operational risk, relevant applications included predicting eligibility criteria performance, amendment likelihood, and site feasibility. Large language models showed a surge in application, appearing in 7 of 33 studies from 2023 alone ^[7]. Some models achieved high predictive performance, with AUROC values reaching 96% on specific tasks, though the review cautioned that selection bias, limited prospective validation, and data quality issues remain active challenges ^[7].

For protocol development specifically, AI-assisted analysis can address several categories of risk simultaneously. Cross-section consistency checking can flag where stated endpoints, objectives, and assessment schedules contradict each other within a single draft. Regulatory precedent retrieval can surface historical agency feedback on similar design choices, including prior rejections or requests for design changes on comparable endpoint strategies. Eligibility criteria analysis can compare proposed inclusion and exclusion criteria against historical trial databases to estimate the size of the eligible population at intended sites. And statistical assumption review can identify where sample size calculations or variance assumptions conflict with published data from the target indication.

Each of these functions corresponds to a category of avoidable or operationally costly amendment. None of them replaces the clinical judgment required to weigh the findings and make design decisions. AI analysis tools operate on the information provided to them and the sources they are configured to access. Clinical reasoning about patient populations, biological plausibility, and investigational rationale requires human expertise those tools cannot substitute. The appropriate framing is that structured AI analysis extends the analytical reach of clinical teams by synthesizing regulatory precedents and cross-document risks faster than manual sequential review allows.

One operational requirement is non-negotiable in this context. AI-assisted protocol analysis for drug development must operate in controlled, auditable environments where proprietary data is protected, sources are transparent to clinical and regulatory reviewers, and outputs meet the documentation standards applicable to IND-stage work. Generic consumer AI tools do not meet those requirements.

An Oncology Endpoint Decision as a Test Case

The webinar included a worked scenario that illustrates what earlier AI-assisted analysis can surface for a development team. Consider a Phase III oncology trial that proposes two co-primary endpoints: overall response rate (ORR) and progression-free survival (PFS). Both endpoints carry regulatory precedent. The clinical team's rationale for the co-primary structure is defensible at the time of drafting. But the structure introduces risks that are not visible without a current reading of agency communications.

A 2023 paper by officials from FDA's Oncology Center of Excellence, titled "Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival," published in the Journal of Clinical Oncology, raised specific concerns about the ability of ORR and PFS to serve as reliable surrogates for overall survival ^[8]. The paper, authored by Merino M, Kasamon Y, Theoret M, Pazdur R, Kluetz P, and Gormley N, noted that ORR and PFS have not been established as validated surrogates for OS under established statistical criteria, and that discordance between these endpoints and OS has emerged across multiple therapeutic areas ^[8]. FDA's August 2025 draft guidance on the assessment of overall survival in oncology trials reinforced the agency's position, stating that OS should be prioritized as the primary endpoint when feasible, given its status as the gold standard for demonstrating efficacy in life-threatening disease ^[9]. That guidance remains in draft status as of this writing and is subject to revision following public comment.

The same regulatory concern is embedded in FDA's own published guidance. The Merino et al. JCO paper explicitly noted that discordance between ORR or PFS and OS has emerged in multiple therapeutic areas, and that the treatment effect on a surrogate endpoint must capture the full effect on the clinical endpoint for that surrogate to be considered validated ^[8]. FDA's August 2025 draft guidance on overall survival adds related regulatory context, noting that OS should be prioritized as the primary endpoint when feasible and that conversion from accelerated to traditional approval increasingly requires mature OS data ^[9]. For a Phase III program with a co-primary ORR-PFS structure, both documents together signal a design choice that warrants closer regulatory review at the drafting stage than it would have received five years ago.

What AI-assisted analysis can do with this scenario is operationally concrete. It can retrieve the current regulatory signal around co-primary ORR and PFS designs, flag the FDA-authored JCO paper's concerns about ORR-PFS discordance, and surface examples of prior trials where comparable endpoint strategies faced approval complications. Presented to the clinical team before the protocol is locked, that analysis creates a real decision point. The team may proceed with the co-primary design and address the review concerns directly in the statistical analysis plan. Or they may restructure the endpoint hierarchy. Either way, the decision is made with the full regulatory context available, rather than discovered during FDA interactions after first-patient-in.

A Practical Protocol Design Checklist Aligned to ICH E8(R1)

ICH E8(R1)'s Quality by Design framework calls for identifying Critical to Quality factors before the protocol is finalized. The guidance defines CtQ factors as design elements whose integrity, if compromised, would undermine study objectives, data reliability, or participant protection ^[4]. Section 3.3 specifies three conditions for effective CtQ identification: establishing a culture that supports open dialogue across functions, focusing on activities essential to the study's objectives, and engaging stakeholders including patients and sites in the planning process ^[4].

For clinical teams working through protocol design, translating that framework into a pre-finalization review means examining at minimum whether:

The primary and key secondary endpoints align with the regulatory precedents and statistical method section without internal contradiction; whether eligibility criteria have been tested against historical site-level data to confirm a realistic eligible population exists; whether the schedule of assessments is operationally executable at the sites intended to conduct the study; whether any adaptive design elements include pre-specified stopping rules with statistical support; and whether the protocol narrative is internally consistent across sections in a way that would survive regulatory and IRB/IEC review without requiring clarifications that trigger amendment requests.

AI-assisted analysis can accelerate the identification of failures in the first, second, and fifth categories above. Human clinical operations review is still required for the third and fourth. Together, they map onto what ICH E8(R1) describes as the prerequisite work for a sound, quality-driven protocol.

Where KScribe Supports Protocol Development Workflows

Kitsa's KScribe product (kitsa.ai/regulatory-document-generation) is built for AI-assisted regulatory document generation across the protocol, informed consent form, investigator brochure, DSUR, and CSR document types [10]. In the context of protocol development, the product is designed to support cross-document consistency and traceable analysis of design decisions, rather than to produce autonomous first drafts.

When a protocol section is updated in KScribe's workflow, the architecture is designed to surface corresponding sections in related documents where the same information must be reflected, reducing the version drift that allows inconsistencies to accumulate across a development package. Audit trails are maintained throughout the workflow, which is relevant to the documentation standards that FDA and EMA have emphasized for AI-assisted processes. As with any AI-assisted tool used in drug development, implementation and validation requirements depend on the specific regulatory context and the sponsor's quality management system. Kitsa's infrastructure is built on SOC 2 Type II, HIPAA, and ISO 27001-certified environments with AWS VPC architecture, designed to meet the data governance requirements of clinical development.

There are also decisions AI analysis should not make. Whether a co-primary endpoint strategy is appropriate for a specific compound, patient population, and competitive context is a scientific and strategic judgment that requires the expertise of clinical, regulatory, and biostatistics leadership. Whether a proposed eligibility criterion reflects a genuine safety boundary or an overly restrictive design assumption is similarly a human call, grounded in biological rationale and site-level insight. AI analysis informs those decisions; it does not resolve them.

Key Takeaways

• Tufts CSDD's 2024 follow-up study found that 76% of Phase I through IV protocols now require at least one amendment, up from 57% in 2015, with an average of 3.3 amendments per protocol and a median direct cost of $535,000 per Phase III amendment.
• The composition of amendments has shifted: the 2024 study found 77% now deemed unavoidable, compared with 55% in the 2016 study. The 23% still avoidable represent a defined financial and timeline target.
• The 260-day average amendment implementation timeline, from internal approval to final oversight approval, means a preventable amendment identified at study startup can account for nearly nine months of processing time. Sites operate under different protocol versions for an average of 215 days during that same window.
• ICH E8(R1), finalized in October 2021, recommends Quality by Design and Critical to Quality factor identification at the protocol design stage, supporting design-time risk analysis rather than post-amendment correction.
• AI-assisted protocol analysis, as described in a 2025 npj Digital Medicine scoping review of 142 studies, can support operational risk prediction including eligibility criteria performance, amendment likelihood, and feasibility assessment.
• FDA's 2023 JCO paper by agency officials, and the agency's August 2025 draft OS guidance, together signal that co-primary ORR and PFS endpoint strategies in oncology warrant closer regulatory review at the drafting stage than in prior years, making early AI-assisted precedent analysis a concrete risk-mitigation step.
• The Kitsa x Hemex partnership reflects a shift toward AI-native CRO infrastructure where protocol reasoning is supported by structured evidence synthesis and cross-document consistency checking rather than disconnected manual research.

FAQ

References

1. [1]Getz K, Smith Z, Botto E, Murphy E, Dauchy A. "New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance." Ther Innov Regul Sci. 2024 May;58(3):539-548. doi: 10.1007/s43441-024-00622-9. PMID: 38438658. https://link.springer.com/article/10.1007/s43441-024-00622-9
2. [2]Getz KA, Stergiopoulos S, Short M, Surgeon L, Krauss R, Pretorius S, Desmond J, Dunn D. "The Impact of Protocol Amendments on Clinical Trial Performance and Cost." Ther Innov Regul Sci. 2016;50(4):436-441. doi: 10.1177/2168479016632271. PMID: 30227022. https://journals.sagepub.com/doi/abs/10.1177/2168479016632271
3. [3]Smith Z, DiMasi J, Getz K. "New Estimates on the Cost of a Delay Day in Drug Development." Ther Innov Regul Sci. 2024. doi: 10.1007/s43441-024-0667-w. Tufts CSDD. https://csdd.tufts.edu/sites/default/files/2025-02/Aug2024%20Day%20of%20Delay%20White%20Paper%20Final.pdf
4. [4]International Council for Harmonisation (ICH). "E8(R1): General Considerations for Clinical Studies." Step 4 Final Guideline, October 2021. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-guideline-e8-r1-general-considerations-clinical-studies_en.pdf
5. [5]International Council for Harmonisation (ICH). "E6(R3): Good Clinical Practice." Adopted at Step 4, January 6, 2025. https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
6. [6]Hemex AG. "About Us." hemex.ch. https://hemex.ch/about-us/
7. [7]Teodoro D, Naderi N, Yazdani A, Zhang B, Bornet A. "A scoping review of artificial intelligence applications in clinical trial risk assessment." npj Digit Med. 2025;8:486. doi: 10.1038/s41746-025-01886-7. PMID: 40731070. https://www.nature.com/articles/s41746-025-01886-7
8. [8]Merino M, Kasamon Y, Theoret M, Pazdur R, Kluetz P, Gormley N. "Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival." J Clin Oncol. 2023 May 20;41(15):2706-2712. doi: 10.1200/JCO.23.00225. PMID: 36888907. https://ascopubs.org/doi/10.1200/JCO.23.00225
9. [9]FDA. "Approaches to the Assessment of Overall Survival in Oncology Clinical Trials." Draft Guidance for Industry, August 2025. Docket No. FDA-2024-D-5850. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/approaches-assessment-overall-survival-oncology-clinical-trials
10. [10]Kitsa. "KScribe: AI-Powered Regulatory Document Generation." kitsa.ai. Accessed June 2026. https://kitsa.ai/regulatory-document-generation
11. [11]Getz KA, Campo RA. "New Benchmarks Characterizing Growth in Protocol Design Complexity." Ther Innov Regul Sci. 2018;52(1):22-28. doi: 10.1177/2168479017713039. PMID: 29714620. https://pubmed.ncbi.nlm.nih.gov/29714620/